Luisa Lina Villa

Citado por

	Todos	Desde 2019
Citações	38609	9121
Índice h	89	47
Índice i10	342	240

2400

1200

600

1800

1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024134 89 135 160 199 316 341 419 633 1024 1632 1942 2020 2018 2184 2285 2372 2252 2146 2126 1963 1860 1833 1850 1849 1615 1513 447

Acesso público

Ver todos

136 artigos

3 artigos

disponível

não disponível

Com base nas autorizações de financiamento

Coautores

Dr. Jorge SalmerónCentro de Investigación en Políticas, Población y Salud. Facultad de Medicina, UNAME-mail confirmado em unam.mx
Enrique BoccardoProfessor of Virology, Institute of Biomedical Sciences, University of São PauloE-mail confirmado em usp.br
Lara TerminiScientific Researcher - ICESP - Faculdade de Medicina da USPE-mail confirmado em hc.fm.usp.br
Ana Paula LepiqueUniversidade de São PauloE-mail confirmado em icb.usp.br
Luiz Carlos ZeferinoProf Titular em Ginecologia, Fac Ciências Médicas. Diretor da Divisão de Oncologia do CAISM, UNICAMPE-mail confirmado em fcm.unicamp.br
Trottier HelenUniversité de Montréal / Sainte-Justine HospitalE-mail confirmado em umontreal.ca
Silvia Helena Rabelo-SantosProfessora de Citologia Clínica, Faculdade de Farmácia, Universidade Federal de GoiásE-mail confirmado em ufg.br
José Humberto Tavares Guerreiro Fre...A. C. Camargo Cancer CenterE-mail confirmado em accamargo.org.br
Christine M. PierceMerck & Co., Inc.E-mail confirmado em merck.com
Sophie DerchainProfessor of Gynecology, State University of CampinasE-mail confirmado em pq.cnpq.br
Itzel E Calleja-MaciasVanguard UniversityE-mail confirmado em vanguard.edu
Tatiana RabachiniUniversity of Bern - SwitzerlandE-mail confirmado em pki.unibe.ch
Salaheddin MahmudProfessor and Canada Research Chair of Pharmaco-epidemiology, University of ManitobaE-mail confirmado em mcgill.ca
Matthew B. Schabath, Ph.D.H. Lee Moffitt Cancer Center & Research InstituteE-mail confirmado em moffitt.org
Silvya Stuchi Maria-EnglerFull Professor of School of Pharmaceutical Sciences, University of São PauloE-mail confirmado em usp.br
Mark SchiffmanNational Cancer InstituteE-mail confirmado em mail.nih.gov
John T. SchillerNational Caner Institute, NIHE-mail confirmado em mail.nih.gov
Luciana Yuki TomitaFederal University of Sao PauloE-mail confirmado em unifesp.br
Marly Augusto CardosoDepartamento de Nutrição, Faculdade de Saúde Pública, Universidade de São PauloE-mail confirmado em usp.br
Suely NonogakiPesquisador científico do Instituto Adolfo LutzE-mail confirmado em ial.sp.gov.br

Seguir

Luisa Lina Villa

Professora de Oncologia Básica, Depto Radiologia da Faculdade de Medicina da Universidade de São

E-mail confirmado em hc.fm.usp.br

câncer epidemiologia biologia molecular papilomavírus humano


Título Ordenar por citações Ordenar por ano Ordenar por título	Citado por Citado por	Ano
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions Future II Study Group New England Journal of Medicine 356 (19), 1915-1927, 2007	2434	2007
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre … LL Villa, RLR Costa, CA Petta, RP Andrade, KA Ault, AR Giuliano, ... The lancet oncology 6 (5), 271-278, 2005	2349	2005
Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer EL Franco, LL Villa, JP Sobrinho, JM Prado, MC Rousseau, M Désy, ... The Journal of infectious diseases 180 (5), 1415-1423, 1999	976	1999
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a … KA Ault The Lancet 369 (9576), 1861-1868, 2007	862	2007
Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia NF Schlecht, S Kulaga, J Robitaille, S Ferreira, M Santos, RA Miyamura, ... Jama 286 (24), 3106-3114, 2001	862	2001
HPV type-distribution in women with and without cervical neoplastic diseases G Clifford, S Franceschi, M Diaz, N Muñoz, LL Villa Vaccine 24, S26-S34, 2006	823	2006
Updating the natural history of HPV and anogenital cancer AB Moscicki, M Schiffman, S Kjaer, LL Villa Vaccine 24, S42-S51, 2006	777	2006
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up LL Villa, RLR Costa, CA Petta, RP Andrade, J Paavonen, OE Iversen, ... British Journal of Cancer 95 (11), 1459-1466, 2006	743	2006
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in … DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... The Journal of infectious diseases 199 (7), 926-935, 2009	696	2009
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 LL Villa, KA Ault, AR Giuliano, RLR Costa, CA Petta, RP Andrade, ... Vaccine 24 (27-28), 5571-5583, 2006	680	2006
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide … HU Bernard, SY Chan, MM Manos, CK Ong, LL Villa, H Delius, CL Peyton, ... Journal of Infectious Diseases 170 (5), 1077-1085, 1994	640	1994
Planning cancer control in Latin America and the Caribbean PE Goss, BL Lee, T Badovinac-Crnjevic, K Strasser-Weippl, ... The lancet oncology 14 (5), 391-436, 2013	623	2013
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study AR Giuliano, JH Lee, W Fulp, LL Villa, E Lazcano, MR Papenfuss, ... The Lancet 377 (9769), 932-940, 2011	591	2011
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts … Future I/II Study Group The BMJ 341, 2010	539	2010
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... Journal of the National Cancer Institute 102 (5), 325-339, 2010	476	2010
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia NF Schlecht, RW Platt, E Duarte-Franco, MC Costa, JP Sobrinho, ... Journal of the National Cancer Institute 95 (17), 1336-1343, 2003	453	2003
Human papillomavirus infections with multiple types and risk of cervical neoplasia H Trottier, S Mahmud, MC Costa, JP Sobrinho, E Duarte-Franco, ... Cancer Epidemiology Biomarkers & Prevention 15 (7), 1274-1280, 2006	437	2006
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States AR Giuliano, E Lazcano-Ponce, LL Villa, R Flores, J Salmeron, JH Lee, ... Cancer Epidemiology Biomarkers & Prevention 17 (8), 2036-2043, 2008	435	2008
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results JT Schiller, X Castellsagué, LL Villa, A Hildesheim Vaccine 26, K53-K61, 2008	422	2008
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ... Cancer prevention research 2 (10), 868-878, 2009	419	2009

O sistema não pode executar a operação agora. Tente novamente mais tarde.

Artigos 1–20

Citações por ano

Citações duplicadas

Citações mescladas

Adicionar coautoresCoautores

Seguir

Citado por

Coautores